AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial (2022)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01293-9
Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138202681
Type: Journal Article/Review
Parent Publication: Clinical Lymphoma Myeloma and Leukemia